<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01238055</url>
  </required_header>
  <id_info>
    <org_study_id>2008-09-031</org_study_id>
    <nct_id>NCT01238055</nct_id>
  </id_info>
  <brief_title>Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer</brief_title>
  <official_title>Randomized Phase II Trial of Sunitinib and Docetaxel in Advanced Gastric Cancer Patients Who Had Prior Chemotherapy With Fluoropyrimidine and Platinum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Sunitinib and Docetaxel is effective in the&#xD;
      treatment of advanced gastric cancer patients who had prior chemotherapy with&#xD;
      fluoropyrimidine and platinum.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized phase II trial of Sunitinib and Docetaxel in advanced gastric cancer&#xD;
      patients who had prior chemotherapy with Fluoropyrimidine and Platinum.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to progression</measure>
    <time_frame>every 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel + Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel and Sunitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel + Sunitinib</intervention_name>
    <description>Docetaxel 60 mg/m2 iv, every 3 weeks&#xD;
Sunitinib 37.5 mg qd daily, every 3 weeks</description>
    <arm_group_label>Docetaxel + Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel only</intervention_name>
    <description>Docetaxel 60 mg/m2 iv</description>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. histologically or cytologically confirmed diagnosis of gastric adenocarcinoma or&#xD;
             gastroesophageal junction adenoca (i.e. an adenocarcinoma with &gt; 50% extension in the&#xD;
             stomach)&#xD;
&#xD;
          2. patients must present with stage IV disease not amenable to surgery, radiation or&#xD;
             combined modality therapy with curative intent. Patients previously undergoing local&#xD;
             treatment (surgery and/or radiation) must have subsequently progressed or recurred&#xD;
&#xD;
          3. prior chemotherapy wit fluoropyrimidine and platinum&#xD;
&#xD;
          4. measurable or evaluable disease according to RECIST&#xD;
&#xD;
          5. age, 18 years or older&#xD;
&#xD;
          6. ECOG performance status 0 - 2&#xD;
&#xD;
          7. adequate organ function as defined by the following criteria absolute neutrophil count&#xD;
             (ANC) ≥ 1,500/ul platelets ≥ 100,000/ul AST/ALT ≤ 2.5 x ULN, ≤ 5.0 x ULN if liver&#xD;
             involvement Total serum bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          8. life expectancy of ≥ 3 months&#xD;
&#xD;
          9. signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. more than one prior chemotherapy for metastatic disease&#xD;
&#xD;
          2. severe co-morbid illness and/or active infections&#xD;
&#xD;
          3. NCI CTCAE Grade 3 hemorrhage from any cause &lt; 4 weeks before enrollment&#xD;
&#xD;
          4. preexisting uncontrolled hypertension as documented by 2 baseline blood pressure&#xD;
             readings taken at least 1 hour apart&#xD;
&#xD;
          5. pregnant or lactating women&#xD;
&#xD;
          6. active CNS metastases not controllable with radiotherapy or corticosteroids&#xD;
&#xD;
          7. active and uncontrollable bleeding from gastrointestinal tract&#xD;
&#xD;
          8. known history of hypersensitivity to study drugs&#xD;
&#xD;
          9. prior treatment with sunitinib&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeeyun Lee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Seoul, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>January 7, 2010</study_first_submitted>
  <study_first_submitted_qc>November 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2010</study_first_posted>
  <last_update_submitted>April 8, 2013</last_update_submitted>
  <last_update_submitted_qc>April 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced gastric cancer</keyword>
  <keyword>sunitinib</keyword>
  <keyword>docetaxel</keyword>
  <keyword>fluoropyrimidine platinum based chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

